DepYmed to Meet with Investors at the 34th Annual Oppenheimer Healthcare Life Sciences Conference
FARMINGDALE, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare diseases and oncology that target the protein tyrosine phosphatase (PTP) family of enzymes.
- FARMINGDALE, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare diseases and oncology that target the protein tyrosine phosphatase (PTP) family of enzymes.
- Today the Company announces that management will be meeting with investors at the 34th Annual Oppenheimer Healthcare Life Sciences Conference held virtually on February 13-14, 2024.
- Interested qualified investors must register for the conference through Oppenheimer’s customer portal, and may arrange meetings either through the conference portal or directly with the Company via email at [email protected] .
- Investors are requested to preregister for the event.